The role of actin bundling protein fascin in the progression of ovarian neoplasms

Purpose of investigation: The aim of the study was to investigate the role of fascin in tumor progression and to investigate the role of fascin on endothelial cell migration and angiogenesis in ovarian neoplasms.

Methods: In the study, 94 malign epithelial ovarian neoplasms, 13 borderline epithelial ovarian neoplasms, 25 serous and mucinous cystadenomas and four normal ovarian tissues were examined by means of immunohistochemistry, using monoclonal antihuman fascin antibody, clone IM20.

Results: Total stromal fascin score in cases of borderline and malign epithelial ovarian tumors was significantly higher compared to normal ovaries and benign epithelial ovarian tumors (.000, p < 0.001). There was no statistically significant difference in terms of total epithelial fascin scores of samples between groups (.080, p > 0.05). Presence of vascular invasion (.000, p < 0.001), psammomatous calcifications (.001, p = 0.001), and lymphocytic infiltration (.000, p < 0.001) were significantly higher in malign neoplasms. There was no significant difference in terms of mean microvessel count and homogeneous or heterogeneous fascin expression of microvessels between the benign and malign groups (respectively p = .228 and p = .143).

Conclusions: This study suggests that up-regulation of fascin in tumoral tissue may promote invasion of ovarian carcinoma by cell-matrix adhesion.

Fascin; lmmunohistochemistry; Cystadenoma; Epithelial ovarian neoplasms; Angiogenesis

[I] Karlan B.Y., Cass I.: "Neoplasms of the ovarian and fallopian tube". In: Danforth's Obstetrics and Gynecology. Scott J.R., Gibbs R.S., Karlan B.Y., Haney A.F. (eds.). 9'h edition, Philadelphia, Lippincott WilIiams &Wilkins, 2003, 971.

[2] Leber T.M., Balkwill F.R.: "Regulation of monocyte MMP-9 production by T NF -alpha and tumour derived soluble factor (MMPSF)". Br. J. Cancer, 1998, 78, 724.

[3] Davidson B., Goldberg I., Berner A., Kristensen G.B., Reich R.: "EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma". Clin Exp. Metastasis, 2003, 20, 161.

[4] Ozalp S., Tamr H.M., Yalcin Q.T., Kabukcuoglu S., Oner U., Uray M.: "Prognostic value of matrix metalloproteinase-9 (gelatinaseB) expression in epithelial ovarian tumors". Eur. J. Gynaecol. Oneal., 2003, 24, 417.

[5] Adams J.C., Clelland J.D., Collet G.D.M., Matsumura F., Yamashiro S., Zhang L.: "Cell-matrix adhesions differentially regulate fascin phosphorylation". Mol. Biol. Cell, 1999, 10, 4177

[6] Cohan C.S., Welnhofer E.A., Zhao L., Matsumura F., Yamashiro S.: "Role of the actin bundling protein fascin in growth cone morphogenesis: localization in filopodia and lamellipodia". Cell Motil. Cytoskel., 2001, 48, 109.

[7] Ishikawa R., Yamashiro S., Kohama K., Matsumura F.: "Regulalion of actin binding and actin bundling activities of fascin by caldesmon coupled with tropomyosin". J. Biol. Chem., 1998, 273, 26991.

[8] Goncharuk V.N., Ross J.S., Carlson J.A.: "Actin-binding protem fascin expression in skin neoplazi". J. Cutan. Pathol., 2002, 29, 430.

[9] Hu W., McCrea P.D., Deavers M., Kavanagh J.J., Kudelka A.P., Verschraegen C.F.: "Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors". Clin. Exp. MetasIasis, 2000, 18, 83.

[10] Jawhari A.U., Buda A., Jenkins M. et al.: "Fascin, an actm bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro". Am. J. Path., 2003, 162, 69.

[11] Grothey A., Hashizume R., Ji H. et al.: "C-erbB-2/Her-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines". Oncogene, 2000, 19, 4864.

[12] Guvakova M.A., Boettiger D., Adams J.C.: "Induction of fascin spikes in breast cancer cells by activation of the insulin-like growth factor-1 receptor". Int. J. Biochem. Cell Biol., 2002, 34, 685.

[13] Maitra A., Iacobuzio-Donahue C., Rahman A. et al.: "Immunohistochemical validation of a novel epithelial and a novel stroma marker of pancreatic ductal adenocarcinoma identified by global express microarrays: sea urchin fascin homolog and heat shock protein 47". Am. J. Clin. Pathol., 2002, 118, 52.

[14] Pelosi G., Pastorino U., Pasini F. et al.: "Independent prognostic value of fascin immunoreactivity in. Stage I non small cell lung cancer". Br. J. Cancer, 2003, 88, 537.

[15] Pelosi G., Barisella M., Pasini F. et al.: "CDl 17 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients". Mod. Pathol., 2004, 17, 711.

[16] Kempf W., Levi E., Kamarashev J. et al.: "Fascin express10n m CD30-positive cutaneous lymphoproliferative disorders". J. Cutan. Pathol., 2002, 29, 295.

[17] Fujimoto J., lchigo S., Hirose R. et al.: "Expression of E-cadhenn and a.- and P- catenin mRNAs in uterine cervical cancers". Tumor Biol., 1997, 18, 206.

[18] Tao Y.S., Edwards R.A., Tubb B. et al.: "Beta catenin associates with the actin-bundling protein fascin in a non cadherin complex" J. Cell. Biol.. 1996, 134, 1271.

[19] Furlong M.T., Morin P.J.: "Rare activation of the TCF/P-Catenm pathway in ovarian cancer". Gynecol. Oneal., 2000, 77, 97.

[20] Wong V., Ching D., McCrea P.D., Firestone G.L.: "Glucocorticoid down-regulation of fascin protein expression is required for steroid-induced formation of tight junctions and cell-cell interactions in rat mammary epithelial tumor cells". J. Biol. Chem., 1999, 274, 5443.

[21] Guan Y., Woo P.L., Rubenstein N.M., Firestone G.L.: "Transforming growth factor-a abrogates the glucocorticoid stimulation of tight junction formation and reverses the steroid-induced downregulation of fascin in rat mammary epithelial tumor cells by a Ras-depentent pathway". Experimental Cell Res., 2002, 273, 1.

[22] Adams J.C., Kureishy N., Taylor A.L.: "A role for syndecan-1 m coupling fascin spike formation by trombospondin-1". J. Cell Biol., 2001, 152, 1169.

[23] Shonukan O.T., Bagayogo I., McCrea P.D., Chao M., Hempstead B.: "Neurotropin-induced melanoma cell migration is mediated through actin-bundling protein fascin". Oncogene, 2003, 22, 3616.

[24] Miiller M., Kramer P.H.: "Integrated cell function: apoptosis". In Arias I.M., Boyer J.L., Chisari F.V., Fausto N., Schachter D., Shafritz D. (eds.), "The Liver Biology and Pathobiology", 4'" edition, Philadelphia, Lippincott Williams &,Wilkins, 2001, 187.

[25] Schneiderman D., Kim J.M., Senterman M., Tsang B.K.: "Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells". Apoptosis, 1999, 4, 271.

[26] Abuharbeid S., Apel J., Zugmaier G. et al.: "Inhibition of Her-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells". Naunyn-Schmiedeberg's Arch. Pharmacol., 2005, 371, 141.

[27] Loizzi V., Chan J.K., Osann K., Cappuccini F., DiSaia P.J., Berman M.L.: "Survival outcomes in patients with reccurent ovarian cancer who were treated with chemoresistance assayguided chemotherapy". Am. J. Obstet. Gynecol., 2003, 189, 1301.

[28] Amis S.J., Coulter-Smith S.D., Crow J.C., Maclean A.B., Perret C.W.: "Microvessel quantification in benign and malignant ovarian tumors". Int. J. Gynecol. Cancer, 2005, 15, 58.

[29] Kryczek I., Lange A., Mottram P. et al.: "CXCL12 and vascular endothelial growth factor synergistica induce neoangiogenesis in human ovarian cancers". Cancer Res., 2005, 65, 465.